基于多准则优化的权衡探索联合RapidPlan在头颈部放疗计划制定中的有效性
本研究提出将多准则优化权衡探索(TO)与RapidPlan(RP)联合用于头颈部VMAT计划优化,对20例既往临床VMAT计划各额外创建5个计划进行比较。结果显示TO联合RP优化的计划在维持靶区覆盖可比的同时显著改善危及器官保护,其中RP_TO+计划腮腺平均剂量降低最明显,但淋巴结PTV的99%体积剂量略降低、95%体积剂量略升高,仍在临床可接受范围内,计划复杂度增加但可实施。
要点
- TO联合RP优化的计划较临床计划显著改善OAR保护且靶区覆盖可比。
- RP_TO+计划腮腺平均剂量最低:左侧15.0±4.6 Gy vs 22.9±5.5 Gy,右侧17.1±5.0 Gy vs 24.8±5.8 Gy。
- RP_TO+淋巴结PTV的99%体积剂量略降低、95%体积剂量略升高,仍在临床可接受范围内。
核心结论
- 在VMAT计划优化中联合使用TO与RP对计划质量的提升最大。
- 对RP_TO+计划而言,接受淋巴结PTV的轻微退化换来了OAR剂量的最大降低。
研究设计与样本
- 选取20例既往临床VMAT计划,为每例患者额外创建5个计划:临床计划经TO进一步优化(Clin+TO)、用自建RP模型生成的两个计划(RP_1为基于VMAT临床计划构建的模型,RP_TO为基于经TO优化的VMAT计划构建的模型)、以及这两个计划再经TO优化生成的RP_1+TO和RP_TO+。
- TO管理标准化为在不损害临床可接受PTV覆盖的前提下最大化腮腺保护。
- 基于OAR和PTV的剂量体积参数、靶区均匀性、适形性以及计划复杂度和可实施性对生成计划进行相互比较。
主要发现
- TO联合RP优化的计划较临床计划显著改善OAR保护,同时维持可比的靶区剂量覆盖。
- RP_TO+计划较临床计划实现最大OAR保护:腮腺平均剂量左侧15.0±4.6 Gy vs 22.9±5.5 Gy,右侧17.1±5.0 Gy vs 24.8±5.8 Gy。
- RP_TO+计划淋巴结PTV的99%体积剂量略降低,95%体积剂量较临床计划略升高(76.0±1.2 vs 77.4±0.6 和 80.9±0.9 vs 79.7±0.4),但仍在临床可接受范围内。
- RP与TO联合优化的计划复杂度增加,但被证明可实施。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A new strategy is introduced combining the use of Multi-Criteria Optimization-based Trade-Off Exploration (TO) and RapidPlan™ (RP) for the selection of optimisation parameters that improve the trade-off between sparing of organs at risk (OAR) and target coverage for head and neck radiotherapy planning. Using both approaches simultaneously; three different workflows were proposed for the optimisation process of volumetric-modulated arc therapy (VMAT) plans. The generated plans were compared to the clinical plans and the plans that resulted using RP and TO individually. METHODS: Twenty clinical VMAT plans previously administered were selected. Five additional plans were created for each patient: a clinical plan further optimised with TO (Clin+TO); two plans generated by in-house built RP models, RP_1 with the model built with VMAT clinical plans and RP_TO with the model built with VMAT plans optimised by TO. Finally, these last two plans were additionally optimised with TO for the creation of the plans RP_1 + TO and RP_TO+ respectively. The TO management was standardised to maximise the sparing of the parotid glands without compromising a clinically acceptable PTV coverage. Resulting plans were inter-compared based on dose-volume parameters for OAR and PTVs, target homogeneity, conformity, and plans complexity and deliverability. RESULTS: The plans optimised using TO in combination with RP showed significantly improved OAR sparing while maintaining comparable target dose coverage to the clinical plans. The largest OAR sparing compared to the clinical plans was achieved by the RP_TO+ plans, which reported a mean parotid dose average of 15.0 ± 4.6 Gy vs 22.9 ± 5.5 Gy (left) and 17.1 ± 5.0 Gy vs 24.8 ± 5.8 Gy (right). However, at the same time, RP_TO+ showed a slight dose reduction for the 99% volume of the nodal PTV and an increase for the 95% (when comparing to the clinical plans 76.0 ± 1.2 vs 77.4 ± 0.6 and 80.9 ± 0.9 vs 79.7 ± 0.4) but remained within clinical acceptance. Plans optimised with RP and TO combined, showed an increase in complexity but were proven to be deliverable. CONCLUSION: The use of TO combined with RP during the optimisation of VMAT plans enhanced plan quality the most. For the RP_TO+ plans, acceptance of a slight deterioration in nodal PTV allowed the largest reduction in OAR dose to be achieved.
引用
- Miguel-Chumacero E, Currie G, Johnston A, et al. Effectiveness of Multi-Criteria Optimization-based Trade-Off exploration in combination with RapidPlan for head & neck radiotherapy planning. Radiat Oncol. 2018. PMID: 30470254. doi:10.1186/s13014-018-1175-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。